Emphysema historical perspective: Difference between revisions
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
* In 1769, Giovanni Morgagni described nineteen cases in which the lungs were “turgid” particularly from air. | * In 1769, Giovanni Morgagni described nineteen cases in which the lungs were “turgid” particularly from air. | ||
* In 1789, [[Matthew Baillie]] illustrated an emphysematous lung and described the destructive character of the condition. | * In 1789, [[Matthew Baillie]] illustrated an emphysematous lung and described the destructive character of the condition. | ||
* In 1837, | * In 1837, René Laennec, the physician who invented the [[stethoscope]], used the term "emphysema" in his book ''A Treatise on the Diseases of the Chest and of Mediate Auscultation'' to describe lungs that did not collapse when he opened the chest during an autopsy. He noted that they did not collapse as usual because they were full of air and the airways were filled with mucus.<ref name="pmid18046898">{{cite journal |author=Petty TL |title=The history of COPD |journal=Int J Chron Obstruct Pulmon Dis |volume=1 |issue=1 |pages=3–14 |year=2006 |pmid=18046898 |pmc=2706597}}</ref> | ||
* In 1842, | * In 1842, John Hutchinson invented the [[spirometer]], which allowed the measurement of the vital capacity of the lungs. However, his spirometer could only measure volume, not airflow.<ref name="pmid15849329">{{cite journal |author=Fishman AP |title=One hundred years of chronic obstructive pulmonary disease |journal=Am. J. Respir. Crit. Care Med. |volume=171 |issue=9 |pages=941–8 |year=2005 |month=May |pmid=15849329 |doi=10.1164/rccm.200412-1685OE}}</ref> | ||
* In 1944, Ronald Christie defined the diagnosis for emphysema based on dyspnea on exertion, after exclusion of bronchospasm, or left ventricular failure. | * In 1944, Ronald Christie defined the diagnosis for emphysema based on dyspnea on exertion, after exclusion of bronchospasm, or left ventricular failure. | ||
* In 1947, Tiffeneau and Pinelli, and in 1950 and 1951, Gaensler described the principles of measuring airflow. | * In 1947, Tiffeneau and Pinelli, and in 1950 and 1951, Gaensler described the principles of measuring airflow. | ||
| Line 21: | Line 21: | ||
* In 1967, Reid described the pathology of emphysema and other components of COPD. | * In 1967, Reid described the pathology of emphysema and other components of COPD. | ||
* In 1976, Thurlbeck’s book (1976) cites Jethro Gough and his first use of whole lung thin sections to illustrate the various types of emphysema. | * In 1976, Thurlbeck’s book (1976) cites Jethro Gough and his first use of whole lung thin sections to illustrate the various types of emphysema. | ||
* In 1980, a clinical trial performed and use of oxygen therapy for emphysema proved. <ref name="pmid6776858">{{cite journal |vauthors= |title=Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group |journal=Ann. Intern. Med. |volume=93 |issue=3 |pages=391–8 |year=1980 |pmid=6776858 |doi= |url=}}</ref> | * In 1980, a clinical trial performed and use of nocturnal oxygen therapy for emphysema proved. <ref name="pmid6776858">{{cite journal |vauthors= |title=Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group |journal=Ann. Intern. Med. |volume=93 |issue=3 |pages=391–8 |year=1980 |pmid=6776858 |doi= |url=}}</ref> | ||
* In 1998, Paggiaro | * In 1998, Paggiaro performed a multicentre clinical trial of corticosteroids for emphysema treatment.<ref name="pmid9519948">{{cite journal |vauthors=Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J |title=Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group |journal=Lancet |volume=351 |issue=9105 |pages=773–80 |year=1998 |pmid=9519948 |doi= |url=}}</ref> | ||
* In 2003, Choe used methylprednisolone to produce emphysema in rats. They conclude that systemic methylprednisolone increases the activity of matrix metalloproteinases in the lung and causes emphysema. <ref name="pmid12522028">{{cite journal |vauthors=Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF |title=Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats |journal=Am. J. Respir. Crit. Care Med. |volume=167 |issue=11 |pages=1516–21 |year=2003 |pmid=12522028 |doi=10.1164/rccm.200210-1207OC |url=}}</ref> | * In 2003, Choe used methylprednisolone to produce emphysema in rats. They conclude that systemic methylprednisolone increases the activity of matrix metalloproteinases in the lung and causes emphysema. <ref name="pmid12522028">{{cite journal |vauthors=Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF |title=Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats |journal=Am. J. Respir. Crit. Care Med. |volume=167 |issue=11 |pages=1516–21 |year=2003 |pmid=12522028 |doi=10.1164/rccm.200210-1207OC |url=}}</ref> | ||
* In 2004, GOLD offered a new classification of the severity of COPD. <ref name="urlGlobal Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD">{{cite web |url=http://goldcopd.org/ |title=Global Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD |format= |work= |accessdate=}}</ref> | * In 2004, GOLD offered a new classification of the severity of COPD. <ref name="urlGlobal Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD">{{cite web |url=http://goldcopd.org/ |title=Global Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD |format= |work= |accessdate=}}</ref> | ||
* In 2005, Voelkel and Taraseviciene-Stewart offered emphysema as an autoimmune vascular disease. <ref name="pmid16113465">{{cite journal |vauthors=Voelkel N, Taraseviciene-Stewart L |title=Emphysema: an autoimmune vascular disease? |journal=Proc Am Thorac Soc |volume=2 |issue=1 |pages=23–5 |year=2005 |pmid=16113465 |doi=10.1513/pats.200405-033MS |url=}}</ref> | * In 2005, Voelkel and Taraseviciene-Stewart offered emphysema as an autoimmune vascular disease. <ref name="pmid16113465">{{cite journal |vauthors=Voelkel N, Taraseviciene-Stewart L |title=Emphysema: an autoimmune vascular disease? |journal=Proc Am Thorac Soc |volume=2 |issue=1 |pages=23–5 |year=2005 |pmid=16113465 |doi=10.1513/pats.200405-033MS |url=}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
| Line 44: | Line 43: | ||
|Giovanni Morgagni | |Giovanni Morgagni | ||
| Described nineteen cases in which the lungs were “turgid” particularly from air | | Described nineteen cases in which the lungs were “turgid” particularly from air | ||
|- | |||
|1789 | |||
|[[Matthew Baillie]] | |||
| | |||
|- | |||
|1837 | |||
|René Laennec | |||
| | |||
|- | |||
|1842 | |||
|John Hutchinson | |||
| | |||
|- | |||
|1944 | |||
|Ronald Christie | |||
| | |||
|- | |||
|1947 | |||
|Tiffeneau and Pinelli | |||
| | |||
|- | |- | ||
|1952 | |1952 | ||
| | |Gough | ||
| | |||
|- | |||
|1956 | |||
|Barach and Bickerman | |||
| | | | ||
|- | |- | ||
| | |1959 | ||
| | |CIBA guest symposium of physicians | ||
| | | | ||
|- | |- | ||
| | |1962 | ||
| | |American Thoracic Society Committee on Diagnostic Standards | ||
| | | | ||
|- | |- | ||
| | |1964 | ||
| | |Gross | ||
| | | | ||
|- | |- | ||
| | |1967 | ||
| | |Reid | ||
| | | | ||
|- | |- | ||
| | |1976 | ||
| | |Thurlbeck | ||
| | | | ||
|- | |- | ||
| | |1980 | ||
| | |Oxygen therapy trial | ||
| | | | ||
|- | |- | ||
| | |1998 | ||
| | |Paggiaro | ||
| | | | ||
|- | |- | ||
|2003 | |2003 | ||
| | |Choe | ||
| | | | ||
|- | |||
|2004 | |||
|GOLD criteria | |||
|New classification of the severity of COPD | |||
|- | |||
|2005 | |||
|Voelkel and Taraseviciene-Stewart | |||
|Emphysema as an autoimmune vascular disease | |||
|} | |} | ||
Revision as of 04:46, 11 November 2017
|
Emphysema Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Emphysema historical perspective On the Web |
|
American Roentgen Ray Society Images of Emphysema historical perspective |
|
Risk calculators and risk factors for Emphysema historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Priyamvada Singh, MBBS [3]
Overview
The terms chronic bronchitis and emphysema were formally defined at the CIBA guest symposium of physicians in 1959. Matthew Baillie illustrated an emphysematous lung in 1789 and described the destructive character of the condition.
Historical Perspective
- In 1679, Bonet for the first time described voluminous lungs.
- In 1721, Ruysh described enlarged lung airspaces in emphysema.
- In 1769, Giovanni Morgagni described nineteen cases in which the lungs were “turgid” particularly from air.
- In 1789, Matthew Baillie illustrated an emphysematous lung and described the destructive character of the condition.
- In 1837, René Laennec, the physician who invented the stethoscope, used the term "emphysema" in his book A Treatise on the Diseases of the Chest and of Mediate Auscultation to describe lungs that did not collapse when he opened the chest during an autopsy. He noted that they did not collapse as usual because they were full of air and the airways were filled with mucus.[1]
- In 1842, John Hutchinson invented the spirometer, which allowed the measurement of the vital capacity of the lungs. However, his spirometer could only measure volume, not airflow.[2]
- In 1944, Ronald Christie defined the diagnosis for emphysema based on dyspnea on exertion, after exclusion of bronchospasm, or left ventricular failure.
- In 1947, Tiffeneau and Pinelli, and in 1950 and 1951, Gaensler described the principles of measuring airflow.
- in 1952, Gough explained the pathology of emphysema.
- In 1956, Barach and Bickerman described treatment for emphysema in their comprehensive textbook.
- In 1959, the terms chronic bronchitis and emphysema were formally defined at the CIBA guest symposium of physicians.
- In 1962, American Thoracic Society Committee on Diagnostic Standards defined the components of COPD and this definition is the foundation of COPD description.
- In 1964, Gross produced destruction of alveoli and hyperinflation, by injection of pancreatic extracts (papain) into the airways of guinea pigs.
- In 1967, Reid described the pathology of emphysema and other components of COPD.
- In 1976, Thurlbeck’s book (1976) cites Jethro Gough and his first use of whole lung thin sections to illustrate the various types of emphysema.
- In 1980, a clinical trial performed and use of nocturnal oxygen therapy for emphysema proved. [3]
- In 1998, Paggiaro performed a multicentre clinical trial of corticosteroids for emphysema treatment.[4]
- In 2003, Choe used methylprednisolone to produce emphysema in rats. They conclude that systemic methylprednisolone increases the activity of matrix metalloproteinases in the lung and causes emphysema. [5]
- In 2004, GOLD offered a new classification of the severity of COPD. [6]
- In 2005, Voelkel and Taraseviciene-Stewart offered emphysema as an autoimmune vascular disease. [7]
| Year | Investigator | Landmark event |
|---|---|---|
| 1679 | Bonet | Described voluminous lungs |
| 1721 | Ruysh | |
| 1769 | Giovanni Morgagni | Described nineteen cases in which the lungs were “turgid” particularly from air |
| 1789 | Matthew Baillie | |
| 1837 | René Laennec | |
| 1842 | John Hutchinson | |
| 1944 | Ronald Christie | |
| 1947 | Tiffeneau and Pinelli | |
| 1952 | Gough | |
| 1956 | Barach and Bickerman | |
| 1959 | CIBA guest symposium of physicians | |
| 1962 | American Thoracic Society Committee on Diagnostic Standards | |
| 1964 | Gross | |
| 1967 | Reid | |
| 1976 | Thurlbeck | |
| 1980 | Oxygen therapy trial | |
| 1998 | Paggiaro | |
| 2003 | Choe | |
| 2004 | GOLD criteria | New classification of the severity of COPD |
| 2005 | Voelkel and Taraseviciene-Stewart | Emphysema as an autoimmune vascular disease |
References
- ↑ Petty TL (2006). "The history of COPD". Int J Chron Obstruct Pulmon Dis. 1 (1): 3–14. PMC 2706597. PMID 18046898.
- ↑ Fishman AP (2005). "One hundred years of chronic obstructive pulmonary disease". Am. J. Respir. Crit. Care Med. 171 (9): 941–8. doi:10.1164/rccm.200412-1685OE. PMID 15849329. Unknown parameter
|month=ignored (help) - ↑ "Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group". Ann. Intern. Med. 93 (3): 391–8. 1980. PMID 6776858.
- ↑ Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J (1998). "Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group". Lancet. 351 (9105): 773–80. PMID 9519948.
- ↑ Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Gera L, Tuder RM, Voelkel NF (2003). "Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats". Am. J. Respir. Crit. Care Med. 167 (11): 1516–21. doi:10.1164/rccm.200210-1207OC. PMID 12522028.
- ↑ "Global Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD".
- ↑ Voelkel N, Taraseviciene-Stewart L (2005). "Emphysema: an autoimmune vascular disease?". Proc Am Thorac Soc. 2 (1): 23–5. doi:10.1513/pats.200405-033MS. PMID 16113465.